Keywords: AstraZeneca, Crestor, FDA, Indications, Heart attack, Stroke, Cancer metabolism drug research, Cancer Resarch UK
AstraZeneca gets wider US indications for Crestor; enters cancer drug development deal with UK charity
Article | 9 February 2010
The US Food and Drug Administration yesterday approved Anglo-Swedish drug major AstraZeneca’s blockbuster cholesterol-lowerer Crestor (rosuvastatin calcium) for additional indications. Last year the drug, which is marketed under license from Japan’s Shionogi, generated revenues for the UK-headquartered firm of $4.5 billion and $1.26 billion in the last three months of 2009, an increase of 20% on the like period of the previous year (The Pharma Letter January 28).
The news was welcomed by investors, who pushed AstraZeneca’s share price up 2.18% to £28.405 by 10.30GMT, in London trading volume of nearly 1.8 million this morning. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
